Guided Therapeutics (GTHP) Non-Current Debt (2010 - 2026)
Guided Therapeutics (GTHP) posted Non-Current Debt of $23000.0 for Q4 2025, down 20.69% sequentially from $29000.0 in Q3 2025, and down 51.06% YoY from $47000.0 in Q4 2024.
Guided Therapeutics (GTHP) Non-Current Debt (2010 - 2026) Analysis & Trends
Guided Therapeutics has reported Non-Current Debt for 16 years, with the latest figure at $23000.0 in Q4 2025.
- Quarterly Non-Current Debt fell 51.06% year-over-year to $23000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23000.0 (down 51.06% YoY) and the FY2025 annual result came in at $23000.0, down 51.06% from the prior year.
- Non-Current Debt eased to $23000.0 in Q4 2025 per GTHP's latest filing, from $29000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $787000.0 in Q3 2021 and troughed at $22770.0 in Q1 2023.
- A 5-year average of $233219.8 and a median of $54784.5 in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2021 and 2022: Non-Current Debt surged 2366.67% in 2021, then sank 94.91% in 2022.
- Over 5 years, Non-Current Debt stood at $592000.0 in 2021, then plunged by 90.44% to $56569.0 in 2022, then soared by 66.44% to $94152.0 in 2023, then sank by 50.08% to $47000.0 in 2024, then slumped by 51.06% to $23000.0 in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $23000.0, $29000.0, and $35000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 14.19 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 26.17 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 10.92 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 598.70 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 10.09 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 7.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 1.65 Bn |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | 53,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 24,003.00 |
| Sep 30, 2023 | 94,152.00 |
| Jun 30, 2023 | 563,000.00 |
| Mar 31, 2023 | 22,770.00 |
| Dec 31, 2022 | 56,569.00 |
| Sep 30, 2022 | 590,000.00 |
| Jun 30, 2022 | 29,462.00 |
| Dec 31, 2021 | 592,000.00 |
| Sep 30, 2021 | 787,000.00 |
| Jun 30, 2021 | 579,000.00 |
| Mar 31, 2021 | 573,000.00 |
| Dec 31, 2020 | 24,000.00 |